Across TCGA pan-cancer cohorts, TMEM132D-AS2 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of TMEM132D-AS2’s most consistent transcriptional readouts.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where TMEM132D-AS2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types TMEM132D-AS2 is over-expressed in tumor.
HNSC and THCA are the cancer types where TMEM132D-AS2 tumor–normal differential expression is most reproducible.